Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Key points: Patients with relapsed CLL achieving complete remission or undetectable minimal residual disease on venetoclax treatment have the most durable responses. Less durable responses are associated with bulky adenopathy, TP53 aberrations, NOTCH1 mutations, and prior refractoriness to B-cell receptor inhibitors.